Inconsistency over paymentBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a2388 (Published 03 November 2008) Cite this as: BMJ 2008;337:a2388
- Terry J Hamblin, visiting professor of haematology1
It seems strange to me that cancer patients who wish to pay for potentially effective treatments that have not yet been approved by the National Institute for Health and Clinical Excellence are charged for their NHS chemotherapy, whereas cancer patients who wish to pay for their definitely ineffective complementary treatment are encouraged to do so and retain their right to NHS chemotherapy.1
Cite this as: BMJ 2008;337:a2388
Competing interests: None declared.